JP7096770B2 - 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 - Google Patents

発現強化座位の使用に基づいた抗体を作製するための組成物および方法 Download PDF

Info

Publication number
JP7096770B2
JP7096770B2 JP2018552794A JP2018552794A JP7096770B2 JP 7096770 B2 JP7096770 B2 JP 7096770B2 JP 2018552794 A JP2018552794 A JP 2018552794A JP 2018552794 A JP2018552794 A JP 2018552794A JP 7096770 B2 JP7096770 B2 JP 7096770B2
Authority
JP
Japan
Prior art keywords
rrs
vector
nucleotide sequence
hcf
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515666A (ja
JP2019515666A5 (enExample
Inventor
ロバート バブ，
ダリャ ブラコフ，
ガン チェン，
ジェイムズ ピー． ファンデル，
ユ ジャオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2019515666A publication Critical patent/JP2019515666A/ja
Publication of JP2019515666A5 publication Critical patent/JP2019515666A5/ja
Priority to JP2021114374A priority Critical patent/JP2021164479A/ja
Application granted granted Critical
Publication of JP7096770B2 publication Critical patent/JP7096770B2/ja
Priority to JP2023201924A priority patent/JP7781128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2018552794A 2016-04-20 2017-04-20 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 Active JP7096770B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021114374A JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2023201924A JP7781128B2 (ja) 2016-04-20 2023-11-29 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
US62/325,400 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021114374A Division JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019515666A JP2019515666A (ja) 2019-06-13
JP2019515666A5 JP2019515666A5 (enExample) 2020-05-28
JP7096770B2 true JP7096770B2 (ja) 2022-07-06

Family

ID=58701851

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552794A Active JP7096770B2 (ja) 2016-04-20 2017-04-20 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2021114374A Pending JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2023201924A Active JP7781128B2 (ja) 2016-04-20 2023-11-29 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021114374A Pending JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2023201924A Active JP7781128B2 (ja) 2016-04-20 2023-11-29 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Country Status (15)

Country Link
US (2) US11512144B2 (enExample)
EP (1) EP3445781A1 (enExample)
JP (3) JP7096770B2 (enExample)
KR (2) KR102547738B1 (enExample)
CN (2) CN109195986B (enExample)
AR (1) AR109451A1 (enExample)
AU (2) AU2017253241B2 (enExample)
BR (1) BR112018071283A2 (enExample)
CA (1) CA3015389A1 (enExample)
EA (1) EA201892010A1 (enExample)
IL (2) IL314779A (enExample)
MX (2) MX2018012868A (enExample)
SG (2) SG10202010155YA (enExample)
TW (2) TWI827531B (enExample)
WO (1) WO2017184832A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021164479A (ja) * 2016-04-20 2021-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
TW202039852A (zh) * 2018-12-21 2020-11-01 美商建南德克公司 核酸之靶向整合
IL286630B2 (en) * 2019-04-02 2025-05-01 Chugai Pharmaceutical Co Ltd Method for introducing a target-specific foreign gene
WO2020264253A1 (en) * 2019-06-26 2020-12-30 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
US20230304062A1 (en) 2021-10-18 2023-09-28 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
MX2024004647A (es) 2021-10-18 2024-05-02 Regeneron Pharma Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus.
EP4453227A1 (en) * 2021-12-22 2024-10-30 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
KR20250022761A (ko) * 2022-06-10 2025-02-17 후지필름 다이오신쓰 바이오테크놀로지스 유케 리미티드 세포의 작출 방법, 헤테로 다량체 단백질의 제조 방법, 바이스페시픽 항체의 제조 방법, 벡터 세트, 포유동물 세포, cho 세포, 및 세포 풀의 작출 방법
US20250122482A1 (en) 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
US20250163468A1 (en) 2023-11-21 2025-05-22 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2009539349A (ja) 2006-06-02 2009-11-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP2012528594A (ja) 2009-06-02 2012-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フコシル化欠損細胞
JP2012531439A (ja) 2009-06-26 2012-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2015519914A (ja) 2012-06-22 2015-07-16 ロンザ バイオロジクス ピーエルシー 部位特異的組込み
JP2016507525A (ja) 2013-02-01 2016-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ定常領域を含む抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
CA2485939C (en) 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
AU2003298674A1 (en) 2002-11-14 2004-06-15 Genentech Inc Intron fusion construct and method of using for selecting high-expressing production cell lines
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2008079943A2 (en) 2006-12-21 2008-07-03 Smithkline Beecham Corporation Novel methods
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
RU2012107634A (ru) * 2009-09-18 2013-10-27 Селексис С.А. Способы и продукты для увеличенной экспрессии и процессинга трансгена
EA201201435A1 (ru) 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI864338B (zh) 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN107109434A (zh) 2014-10-23 2017-08-29 瑞泽恩制药公司 新颖cho整合位点和其用途
RS62859B1 (sr) 2015-09-23 2022-02-28 Regeneron Pharma Optimizovana anti-cd3 bispecifična antitela i njihove upotrebe
CN109195986B (zh) * 2016-04-20 2023-01-03 瑞泽恩制药公司 基于使用表达增强性基因座来制备抗体的组合物和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539349A (ja) 2006-06-02 2009-11-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2012528594A (ja) 2009-06-02 2012-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フコシル化欠損細胞
JP2012531439A (ja) 2009-06-26 2012-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2015519914A (ja) 2012-06-22 2015-07-16 ロンザ バイオロジクス ピーエルシー 部位特異的組込み
JP2016507525A (ja) 2013-02-01 2016-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ定常領域を含む抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotechnol. Prog. (2015) Vol.31, No.6, pp.1645-1656
Cytotechnology (2006) Vol.51, pp.171-182

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021164479A (ja) * 2016-04-20 2021-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Also Published As

Publication number Publication date
US20190233544A1 (en) 2019-08-01
BR112018071283A2 (pt) 2019-02-12
IL314779A (en) 2024-10-01
MX2018012868A (es) 2019-03-11
JP2019515666A (ja) 2019-06-13
AU2024220124A1 (en) 2024-10-17
MX2025003852A (es) 2025-05-02
WO2017184832A1 (en) 2017-10-26
TW201803986A (zh) 2018-02-01
AU2017253241A1 (en) 2018-09-20
KR20230098361A (ko) 2023-07-03
IL262266B2 (en) 2025-01-01
JP7781128B2 (ja) 2025-12-05
KR20180134893A (ko) 2018-12-19
CN116515757A (zh) 2023-08-01
AR109451A1 (es) 2018-12-12
JP2024023449A (ja) 2024-02-21
EA201892010A1 (ru) 2019-03-29
TWI827531B (zh) 2024-01-01
CN109195986B (zh) 2023-01-03
EP3445781A1 (en) 2019-02-27
CA3015389A1 (en) 2017-10-26
IL262266A (en) 2018-11-29
US20230130799A1 (en) 2023-04-27
SG10202010155YA (en) 2020-11-27
IL262266B1 (en) 2024-09-01
US11512144B2 (en) 2022-11-29
KR102547738B1 (ko) 2023-06-26
JP2021164479A (ja) 2021-10-14
TW202415767A (zh) 2024-04-16
CN109195986A (zh) 2019-01-11
AU2017253241B2 (en) 2024-07-04
SG11201807885PA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
JP7546015B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7096770B2 (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP7789143B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220405

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220412

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220624

R150 Certificate of patent or registration of utility model

Ref document number: 7096770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250